NervGen Pharma Corp. (NGEN.V)
CAD 2.46
(-7.17%)
CAD 2.46
(-7.17%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.38 CAD | -11.76% |
| 2022 | -0.34 CAD | -6.25% |
| 2021 | -0.32 CAD | 8.57% |
| 2020 | -0.35 CAD | 5.41% |
| 2019 | -0.37 CAD | -641.48% |
| 2018 | -0.05 CAD | -12375.0% |
| 2017 | -0.00 CAD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.04 CAD | 72.71% |
| 2024 Q2 | -0.13 CAD | -187.96% |
| 2023 Q2 | -0.08 CAD | 2.19% |
| 2023 Q1 | -0.08 CAD | 6.8% |
| 2023 FY | - CAD | -11.76% |
| 2023 Q4 | -0.14 CAD | -93.37% |
| 2023 Q3 | -0.07 CAD | 9.95% |
| 2022 Q1 | -0.11 CAD | -22.22% |
| 2022 FY | - CAD | -6.25% |
| 2022 Q4 | -0.09 CAD | -27.83% |
| 2022 Q3 | -0.07 CAD | 46.92% |
| 2022 Q2 | -0.13 CAD | -18.18% |
| 2021 FY | - CAD | 8.57% |
| 2021 Q4 | -0.09 CAD | -0.33% |
| 2021 Q3 | -0.09 CAD | -23.55% |
| 2021 Q2 | -0.07 CAD | -14.51% |
| 2021 Q1 | -0.06 CAD | 51.23% |
| 2020 Q3 | -0.06 CAD | 26.24% |
| 2020 FY | - CAD | 5.41% |
| 2020 Q1 | -0.06 CAD | 36.8% |
| 2020 Q2 | -0.09 CAD | -36.87% |
| 2020 Q4 | -0.13 CAD | -103.76% |
| 2019 Q4 | -0.10 CAD | -19.47% |
| 2019 Q2 | -0.06 CAD | 65.5% |
| 2019 Q1 | -0.16 CAD | -302.01% |
| 2019 Q3 | -0.08 CAD | -51.63% |
| 2019 FY | - CAD | -641.48% |
| 2018 Q2 | -0.00 CAD | -500.0% |
| 2018 Q3 | -0.02 CAD | -691.67% |
| 2018 Q4 | -0.04 CAD | -109.47% |
| 2018 FY | - CAD | -12375.0% |
| 2018 Q1 | -0.00 CAD | 0.0% |
| 2017 FY | - CAD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Arch Biopartners Inc. | -0.05 CAD | -612.946% |
| Covalon Technologies Ltd. | -0.18 CAD | -111.111% |
| Hemostemix Inc. | -0.03 CAD | -1154.125% |
| Universal Ibogaine Inc. | -0.06 CAD | -572.566% |
| Kane Biotech Inc. | -0.04 CAD | -958.496% |
| MedMira Inc. | -0.00 CAD | -9900.0% |
| Marvel Biosciences Corp. | -0.06 CAD | -557.439% |
| XORTX Therapeutics Inc. | -1.44 CAD | 73.611% |